- Webcast and Conference Call to Be Held Thursday, August 2, 8:30
a.m. EDT -
WALTHAM, Mass.--(BUSINESS WIRE)--
Repligen Corporation (NASDAQ:RGEN) today announced it will report
financial results for the second quarter of 2012 before the NASDAQ
Global Market opens on Thursday, August 2. The earnings press release
will be followed by a conference call and webcast at 8:30 a.m. EDT. The
call will be hosted by Walter C. Herlihy, Ph.D., President and CEO of
Repligen, to discuss financial results and highlights for the second
quarter and to provide a corporate update.
The live conference call can be accessed by dialing (866) 543-6407
for domestic callers or (617) 213-8898 for international callers.
Dial-in participants must provide the passcode 51406171. The
webcast can be accessed at the Investors section of Repligen’s website www.repligen.com.
Both the conference call and webcast will be archived for a period of
time following the live event. The replay dial-in numbers are (888)
286-8010 for domestic callers and (617) 801-6888 for international
callers. Replay listeners must provide the passcode 79641908.
About Repligen Corporation
Repligen Corporation is a leading supplier of critical biologic products
used to manufacture biologic drugs. Repligen also applies its expertise
in biologic product development to RG1068, a synthetic hormone being
developed as a novel imaging agent for the diagnosis of a variety of
pancreatic diseases. In addition, the Company has two central nervous
system (CNS) rare disease programs in Phase 1 clinical trials.
Repligen’s corporate headquarters are located at 41 Seyon Street,
Building #1, Suite 100, Waltham, MA 02453.
This press release may contain forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical
statements including, without limitation, statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those anticipated, including, risks discussed from time to time in our
filings with the Securities and Exchange Commission. We expressly
disclaim any responsibility to update forward-looking statements, except
as required by law.
Repligen Corporation
Sondra S. Newman, 781-419-1881
Director
Investor Relations
snewman@repligen.com
Source: Repligen Corporation